The first and only anti-CGRP treatment with dual indications TORONTO, Feb. 25, 2021 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce that Emgality® (galcanezumab) is now indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results